However, the diagnostic performance of the current clinical practice tumor markers, CEA and CA19-9, has been demonstrated to be poor, especially for stratifying the early stages of CRC [28, 29], which was further confirmed in our study. The gene discussed is CEACAM5; the disease is neoplasm.